Gene therapy has proven to be a groundbreaking treatment for individuals living with rare diseases like muscular dystrophy and cystic fibrosis. However, while emerging gene therapy treatments have the potential to be lifesaving, they are also posing significant affordability challenges for patients.
In our upcoming conversation on Jan. 18, “5 Slides We’re Discussing: Gene therapy and the promise for rare disease,” three rare disease experts will discuss gene therapy’s poyrnyisl to treat life-threatening rare diseases, and how to navigate its financial barriers so that this treatment can be affordable and accessible to those who need it.
Rafael Fonseca, chief innovation officer at Mayo Clinic, Jennifer Hodge, U.S. D.M.D. gene therapy lead at Pfizer, Danny Seiden, president and chief executive officer at the Arizona Chamber of Commerce and Industry, and Dr. Sharon Hesterlee, chief research officer at the Muscular Dystrophy Association, will convene to discuss how this issue is impacting Arizonans and what can be done to make these treatments more accessible.
Join us for an engaging virtual conversation as each of our panelists brings their unique perspectives, data points, and questions to help guide our understanding of this issue. The event is free to attend — register here to join us!